Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 23 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 10517889

    Modulators of SMAD7 expression

    Ionis Pharmaceuticals, Inc. · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted

  2. US 10517491

    Cardiac phase-resolved non-breath-hold 3-dimensional magnetic resonance angiography

    The Regents of the University of California · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted

  3. US 10517917

    Compositions and methods for preventing or treating pulmonary hypertension

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 31, 2019 · Expires Dec 26, 2039

    granted

  4. US 10508136

    Peptides and compositions for prevention of cell adhesion and methods of using same

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Dec 17, 2019 · Expires Dec 12, 2039

    granted

  5. US 10501551

    Multivalent and multispecific 41BB-binding fusion proteins

    Inhibrx, Inc. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  6. US 10500177

    Glutarate compounds for treating ischemia-reperfusion injuries

    The Regents of the University of California · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  7. US 10500208

    Emulsion formulations of aprepitant

    Heron Therapeutics, Inc. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  8. US 10501740

    Compositions and methods for inhibiting expression of factor V

    Alnylam Pharmaceuticals, Inc. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  9. US 10501528

    Immunoglobulin single variable domain antibody against RSV prefusion F protein

    The United States of America, as represented by the Secretary, Health and Human Services · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  10. US 10501742

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Dec 10, 2019 · Expires Dec 5, 2039

    granted

  11. US 10485879

    Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues

    Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health · Granted Nov 26, 2019 · Expires Nov 21, 2039

    granted

  12. US 10479993

    Modulation of signal transducer and activator of transcription 3 (STAT3) expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted

  13. US 10478508

    Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted

  14. US 10479868

    Polymeric stabilizing formulations

    Nano Precision Medical, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted

  15. US 10478500

    Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression

    Alnylam Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted

  16. US 10478448

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 19, 2019 · Expires Nov 14, 2039

    granted

  17. US 10471076

    Compositions and methods to treat vision disorders

    The Regents of the University of California · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

  18. US 10472629

    Methods and compositions for modlating apolipoprotein (A) expression

    Ionis Pharmaceuticals, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

  19. US 10472412

    Bispecific multivalent fusion proteins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

  20. US 10472628

    Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 12, 2019 · Expires Nov 7, 2039

    granted

  21. US 10463674

    Process for manufacturing sterile ophthalmic pharmaceutical suspensions

    SENTISS PHARMA PRIVATE LIMITED · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  22. US 10456373

    Agent exhibiting anti-stress, anxiolytic and anti-depression activity, and composition based thereon

    OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYU “NORMOFARM” · Granted Oct 29, 2019 · Expires Oct 24, 2039

    granted

  23. US 10449232

    Puma protein expression vector and use thereof in gene therapy

    The Regents of the University of California · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  24. US 10450384

    Compositions of alpha-1 antitrypsin fusion molecules

    The Regents of the University of Colorado · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.